OPEN ACCESS Freely available online

Mycobacterial Diseases

Opinion Article

Exploring the Mechanisms of Mycobacterial Virulence in Tuberculosis

Megha Sharma*

Department of Surgery, College of Human Medicine, Michigan State University, Michigan, USA

DESCRIPTION

Mycobacteria are a group of bacteria that includes several pathogenic species, such as *Mycobacterium tuberculosis*, the causative agent of Tuberculosis (TB). TB is a major public health concern worldwide, with an estimated 1.5 million deaths in 2020 alone. The virulence of mycobacteria is attributed to several factors, including their ability to evade the host immune system, persist in a dormant state, and resist antibiotic treatment. One of the key factors contributing to mycobacterial virulence is their unique cell wall composition. Mycobacteria have a thick, waxy cell wall that is composed of mycolic acids, which are long-chain fatty acids that form a hydrophobic barrier. This cell wall structure protects the bacteria from the host immune system and makes them resistant to many antibiotics.

Another important factor in mycobacterial virulence is their ability to manipulate host immune responses. Mycobacteria can survive and replicate within phagocytic cells such as macrophages, which are normally responsible for engulfing and destroying invading microorganisms. Mycobacteria can evade the killing mechanisms of macrophages by inhibiting the fusion of lysosomes, which contain enzymes that can break down the bacteria. This allows the bacteria to replicate within the macrophages and establish a chronic infection. Mycobacteria also have several mechanisms for suppressing the host immune response. For example, they can interfere with the production of cytokines, which are signaling molecules that activate immune cells. Mycobacteria can also inhibit the maturation of dendritic cells, which are important for activating T cells, a type of immune cell that is critical for controlling mycobacterial infections.

Another factor contributing to mycobacterial virulence is their ability to persist in a dormant state. Mycobacteria can enter a non-replicating state known as dormancy, which allows them to evade immune responses and survive in a latent form. This dormancy is thought to be a major factor in the development of latent TB, which affects an estimated one-third of the world's population. To survive in a dormant state, mycobacteria must be able to adapt to low-nutrient environments. They can do this by altering their metabolic pathways and utilizing alternative energy sources. For example, they can metabolize host lipids, which allows them to survive in the nutrient-poor environment of the macrophage. Finally, mycobacteria have developed resistance to many antibiotics, which contributes to their virulence. This resistance is largely due to the unique structure of their cell wall, which makes it difficult for antibiotics to penetrate and reach their target. Despite the challenges posed by mycobacterial virulence, there has been significant progress in the development of new therapies for TB. One promising approach is the use of host-directed therapies, which target the host immune response rather than the bacteria themselves. For example, drugs that stimulate the immune response or inhibit the mechanisms by which mycobacteria suppress the immune response have shown promise in clinical trials.

CONCLUSION

The mycobacterial virulence is a complex phenomenon that involves multiple factors, including the unique cell wall composition of these bacteria, their ability to evade and manipulate host immune responses, their ability to persist in a dormant state, and their resistance to antibiotics. In addition, mycobacteria have developed several mechanisms for inactivating antibiotics or pumping them out of the cell. Despite these challenges, there is hope for the development of new therapies that can overcome the virulence of mycobacteria and improve the treatment of TB.

Correspondence to: Megha Sharma, Department of Surgery, College of Human Medicine, Michigan State University, Michigan, USA, E-mail: meghabutolia@gmail.com

Received: 01-Mar-2023, Manuscript No. MDTL-23-23161; **Editor assigned:** 03-Mar-2023, Pre QC No. MDTL-23-23161 (PQ); **Reviewed:** 17-Mar-2023, QC No. MDTL-23-23161; **Revised:** 24-Mar-2023, Manuscript No. MDTL-23-23161 (R); **Published:** 31-Mar-2023, DOI: 10.35248/2161-1068.23.13.333.

Citation: Sharma M (2023) Exploring the Mechanisms of Mycobacterial Virulence in Tuberculosis. Mycobact Dis. 13:333.